desipramine has been researched along with Leukemia P388 in 1 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Leukemia P388: An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jaffrézou, JP | 1 |
| Chen, KG | 1 |
| Durán, GE | 1 |
| Muller, C | 1 |
| Bordier, C | 1 |
| Laurent, G | 1 |
| Sikic, BI | 1 |
| Levade, T | 1 |
1 other study available for desipramine and Leukemia P388
| Article | Year |
|---|---|
Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance.
Topics: Affinity Labels; Animals; Desipramine; Doxorubicin; Drug Interactions; Drug Resistance, Multiple; In | 1995 |